This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furuta, J. Articles by Ushijima, T. Search for Related Content PubMed PubMed Citation Articles by Furuta, J. Articles by Ushijima, T.

Silencing of Peroxiredoxin 2 and Aberrant Methylation of 33 CpG Islands in Putative Promoter Regions in Human Malignant Melanomas

¹ Carcinogenesis Division, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo, Japan; ² Department of Dermatology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ten-noudai, Tsukuba, Ibaraki, Japan; and ³ Department of Dermatology, Faculty of Medicine, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan

Requests for reprints: Toshikazu Ushijima, Carcinogenesis Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. Phone: 81-3-3542-2511; E-mail: tushijim{at}ncc.go.jp.

Aberrant methylation of promoter CpG islands (CGI) is involved in silencing of tumor suppressor genes and is also a potential cancer biomarker. Here, to identify CGIs aberrantly methylated in human melanomas, we did a genome-wide search using methylation-sensitive representational difference analysis. CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes. Among these genes, Peroxiredoxin 2 (PRDX2) was expressed in normal melanocytes, and its expression was lost in melanomas with methylation. The loss of expression was restored by treatment of melanomas with a demethylating agent 5-aza-2'-deoxycytidine. In surgical melanoma specimens, methylation of PRDX2 was detected in 3 of 36 (8%). Furthermore, immunohistochemical analysis of PRDX2 showed that disappearance of immunoreactivity tends to associate with its methylation. PRDX2 was recently reported to be a negative regulator of platelet-derived growth factor signaling, and its silencing was suggested to be involved in melanomas. On the other hand, 12 CGIs were methylated in 9 of the 13 melanoma cell lines and are considered as candidate melanoma biomarkers. (Cancer Res 2006; 66(12): 6080-6)

This article has been cited by other articles:

				J.-H. Kim, P. N. Bogner, S.-H. Baek, N. Ramnath, P. Liang, H.-R. Kim, C. Andrews, and Y.-M. Park Up-Regulation of Peroxiredoxin 1 in Lung Cancer and Its Implication as a Prognostic and Therapeutic Target Clin. Cancer Res., April 15, 2008; 14(8): 2326 - 2333. [Abstract] [Full Text] [PDF]

				M. R.H. Estecio, P. S. Yan, A. E.K. Ibrahim, C. S. Tellez, L. Shen, T. H.-M. Huang, and J.-P. J. Issa High-throughput methylation profiling by MCA coupled to CpG island microarray Genome Res., October 1, 2007; 17(10): 1529 - 1536. [Abstract] [Full Text] [PDF]

				V. Muthusamy, S. Duraisamy, C. M. Bradbury, C. Hobbs, D. P. Curley, B. Nelson, and M. Bosenberg Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma Cancer Res., December 1, 2006; 66(23): 11187 - 11193. [Abstract] [Full Text] [PDF]